#1Enabling a Healthier World Half-Year Results 2022 Pierre-Alain Ruffieux, CEO Philippe Deecke, CFO 22 July 2022 Lonza#2Contents Half-Year 2022 Corporate Overview Half-Year 2022 Financial Summary Half-Year 2022 Divisional Overview Concluding Remarks Q&A Lonza 2#3Half-Year 2022 Corporate Overview Lonza 3#4Group Overview - Solid H1 performance, with CHF 3 billion sales and 16.8% CER growth CHF 987 million CORE EBITDA resulting in a margin of 33.1% ~CHF 500 million investment announced in Fill & Finish (part of planned CAPEX) Group Outlook 2022 confirmed at low to mid-teens CER sales growth and CORE EBITDA margin improvement Continuing to navigate the macroeconomic context (including uncertainties around inflation, supply chain and energy) Lonza 4 CORE definition: See appendix#5Business Environment - Operating in industry that is less sensitive to economic fluctuations Continued demand for CDMO services across healthcare industry Specific interest in flexible business models and end- to-end offerings Lonza 5#6Priorities for 2022 Continued focus on growth momentum and operational excellence Lonza - - Deliver CAPEX investment projects to support long-term growth Meet financial targets by focusing on operational excellence and lean approach to business Maintain focus on innovation and differentiation across technologies, modalities and business models Continue to advance ESG agenda Manage and minimize challenges arising from macroeconomic context 6#7Landmark investment in Fill & Finish to complete the value chain Delivering end-to-end solutions for our customers - ~CHF 500 million investment to build large-scale, commercial drug product fill and finish facility Fulfills strategic commitment to establish a commercial fill and finish offering Investment completes Lonza's integrated end-to-end customer offering Project expected to be completed in 2026 Image by PharmaPlan Agreement signed on June 30, 2022 Lonza Lonza#8Delivering CAPEX projects to support long term growth Expanding offering across modalities. Bend, US Small Molecules • Early clinical phase development and manufacturing facility Visp, CH Biologics Opening of Kodiak's facility in Lonza's IbexⓇ Dedicate Biopark • Commercial mRNA capacity Stein, CH Biologics • New large-scale, commercial drug product fill and finish facility I I I Lonza Continuous investment in an ambitious portfolio of projects to meet the future needs of our customers - Investment across divisions to expand capabilities H1 2022 CAPEX reported at 28.2% of Sales Tampa, US Small Molecules • Expanded inhalation capabilities Puebla, MX Capsules and Health Ingredients New capsule production line. Further lines in Greenwood (US), Haryana (IN), Suzhou (CN), Colmar (FR) L CAPEX investments coming online in H1 2022 Nansha, CN Small Molecules • Extended cGMP HPAPI lab capacities and capabilities Investments announced in H1 2022 (part of planned CAPEX) 8#9Continuing to advance our ESG agenda At the heart of our approach to long-term value creation. Lonza ESG targets incorporated into employee and executive renumeration policy - Investment completed to enable a 20% reduction in industrial water consumption at Visp by recycling water for steam production - More than 100 projects across the business to help us meet our ESG targets 6#10Half-Year 2022 Financial Summary Lonza 10#11Financial Highlights Solid Sales and earnings growth Solid growth from continued business momentum Robust profitability against inflationary backdrop 1 Constant Exchange Rate. Comparison vs. H1 2021 2 Actual Exchange Rate. Comparison vs. H1 2021 Financial Performance Summary in m CHF Sales CORE EBITDA Lonza H1 2022 Change CER¹ Change AER² 2,982 16.8% 17.3% 987 15.3% 16.5% CORE EBITDA margin 33.1% (0.4)ppts (0.2)ppts CORE definition: See appendix 11#12CORE EBITDA Margin Robust profitability in challenging macro environment CORE EBITDA Margin Evolution H1 2022 vs H1 2021 in % Growth projects less dilutive vs H1 2021 Inflation and higher spending levels post-COVID partially offset by productivity Dilutive impact of third-party sales to former Lonza Specialty Ingredients H1 2021 CORE EBITDA margin Growth project impact Productivity/ operational excellence¹ Business mix / one-offs Third party Sales to former Specialty Ingredients business H1 2022 CORE EBITDA margin 1Includes inflationary impact Lonza 33.3 (0.9) 33.1 1.9 (0.7) CORE definition: See appendix (0.5) 12#13Divisional Performance Continued momentum across Divisions Continued strong Biologics growth with some mix dilution Small Molecules impacted by phasing of customer deliveries, but strong margin from mix Lonza Financial Results by Division H1 2022 CORE Sales growth CER1 EBITDA Margin change AER² margin Biologics 26.2% 37.3% (0.9)ppts Small Molecules (21.3)% 29.9% 2.6ppts Strong performance in Cell & Gene helped by a one-off Capsules & Health Ingredients with strong performance, mitigating inflation and supply constraints 1 Constant Exchange Rate. Comparison vs. H1 2021 2 Actual Exchange Rate. Comparison vs. H1 2021 Cell & Gene 23.4% 22.4% 6.3ppts Capsules & Health 4.0% 35.2% Ingredients (0.2)ppts Lonza 16.8% 33.1% (0.2)ppts CORE definition: See appendix 13#14H1 Sales in Small Molecules Sales impacted by phasing of deliveries - Sales expected in H1 delayed into H2 due to phasing of major shipments to contracted customers CDMO business model offers flexibility to customers on pick-up timings of contracted product Fully contracted make-to-order production mitigates risk of inventory obsolescence High utilization of asset base and underlying divisional business remains strong Lonza 14#15CAPEX >80% of investments to support growth Large, diversified project portfolio Internal return thresholds: ROIC 30%, IRR 15-20% Investments backed by contracted demand and customer pipeline 1 Includes investments in Shared Infrastructure 2 Total project CAPEX >50m 3 Total project CAPEX <50m Lonza H1 2021 Project Portfolio CAPEX Breakdown by Division in m CHF in % 28.2% 841 H1 2022 Total: CHF841m Biologics Small Molecules Cell & Gene % Sales Capsules & Health Ingredients Corporate¹ Large growth projects² Small growth projects³ Maintenance 15#16Operational Free Cash Flow Investments in growth and safety of supply Higher CAPEX reflects strategic focus on growth investments Inventory buildup to Lonza Operational Free Cash Flow1 in m CHF H12022 Change H12021 EBITDA 934 376 558 Change of net working capital (492) (255) (237) (NWC) CAPEX (841) (367) (474) 68 (328) 3962 Operational FCF before acq./div (331) (574) 243 NWC as % sales 20.7% 2.4ppts 18.3% CAPEX as % sales 28.2% 9.6ppts 18.6% Other ensure security of supply 'The Operational Free Cash Flow refers to "continuing operations" excluding the Specialty Ingredients business, that was sold on 1 July 2021 and therefore reported as discontinued operations 2Includes non-cash reversal of Gamsenried (CH) environmental remediation provision of CHF 284m in H1 2021 16#17H1 and H2 Performance Balanced underlying H1 and H2 performance expected H12022 H2 2022 Lonza FY 2022 in-line with guidance Sales growth CER¹ Third-party Sales to former Specialty Ingredients Large customer cancellation fee Sales phasing in Small Molecules Delivery of Small Molecules orders produced in H1 Large customer cancellation not yet fully backfilled Low to mid-teens CER1 sales growth CORE EBITDA margin Growth project profitability Large customer cancellation fee Inflationary pressure 1 Constant Exchange Rate 22024 CORE EBITDA margin Mid-Term Guidance of ~33-35% Phasing of corporate cost items Inflationary pressure Improvement in- line with MTG2 trajectory CORE definition: See appendix 17#18Half-Year 2022 Divisional Overview Lonza ood 18#19Biologics Financial and operational performance in H1 2022 1,625m Sales (CHF) 606m CORE EBITDA (CHF) +26.2%¹ +23.7% 37.3% CORE EBITDA Margin Bordered figures are a comparison vs. Half-Year 2021 1 Sales growth % is at constant exchange rate (CER) - Lonza Growth supported by strong demand for commercial capacity Sustained customer demand for flexibility of IbexⓇ offering - New early phase capabilities in monoclonal antibodies launched to capture growing demand for new molecular formats -0.9ppts - Softer H1 margins compared to H1 2021 reflect product mix CORE definition: See appendix 19#20Small Molecules Financial and operational performance in H1 2022 Lonza Lower sales arising from phasing of major shipments to contracted customers - Long-term pipeline reflected by sustained momentum in new program signings 288m Sales (CHF) 86m CORE EBITDA (CHF) 29.9% CORE EBITDA Margin -21.3%¹ - -13.1% +2.6ppts Bordered figures are a comparison vs. Half-Year 2021 1 Sales growth % is at constant exchange rate (CER) Capacity expansions in Nansha (CN), Bend (US) and Tampa (US) successfully executed and currently in ramp up phase - Margin increase compared to H1 2021, driven by growth projects, high utilization and portfolio mix CORE definition: See appendix 20 20#21Cell & Gene Financial and operational performance in H1 2022 344.m Sales (CHF) 77m CORE EBITDA (CHF) +23.4%¹ +75.0% 22.4% CORE EBITDA Margin Bordered figures are a comparison vs. Half-Year 2021 1 Sales growth % is at constant exchange rate (CER) +6.3ppts - Lonza Cell and Gene Technologies: continued focus on scale up of late- stage clinical and commercial products Personalized Medicine: launch of second-generation instrument of Cocoon offering magnetic selection to improve cell purification. Commercialization of CocoonⓇ on track Bioscience: strong customer demand with expectation to maintain growth and profitability Excluding a one-time event, margin is broadly stable compared to H1 2021 CORE definition: See appendix 21#22Capsules & Health Ingredients (CHI) Financial and operational performance in H1 2022 Lonza 625m Sales (CHF) 220m CORE EBITDA (CHF) 35.2% CORE EBITDA Margin +4.0%¹ +3.3% -0.2ppts - ― Continued momentum driven by specialty capsules - Expansion of capsule offering to include titanium dioxide-free white hard gelatin capsules compliant with European regulation On track to deliver 260bn annualized capsule capacity by year-end Robust margin compared to H1 2021 as pricing strategy contributes to offset inflationary pressures Bordered figures are a comparison vs. Half-Year 2021 1 Sales growth % is at constant exchange rate (CER) CORE definition: See appendix 22 22#23Concluding Remarks Lonza 23#24Concluding Remarks Solid H1 performance, with CHF 3 billion sales, 33.1% CORE EBITDA margin and 16.8% CER sales growth - Full Year 2022 Outlook and Mid-Term Guidance reconfirmed 2022 priorities remain unchanged: - Executing on planned investments - - Meet targets through operational excellence and long-term value creation Maintain focus on innovation and differentiation Continue to advance our ESG agenda Continue to drive success by managing the macro economic context Lonza CORE definition: See appendix 24#25Q&A Lonza 261#26Appendices Lonza 27#27Half-Year 2022 Financial Highlights (1/2) Continuing Operations¹ HY 2022 HY 2021 CHF million Sales CORE EBITDA Lonza YoY (in %) 2,982 987 2,542 847 33.3% 17.3 16.5 Margin in % 33.1% EBITDA 934 558 67.4 Margin in % 31.3 22.0 EBIT 645 317 103.5 Margin in % 21.6 12.5 ROIC in % 11.7 11.5 1.7 Net Financial Result (52) (22) 136.4 Tax Rate in % 16.2 11.2 Profit for the Period 498 263 89.4 1 All financial information referring to "continuing operations" are exclusive of the Specialty Ingredients business, that was sold on 1 July 2021 and therefore reported as discontinued operations CORE definition: See appendix 27#28Half-Year 2022 Financial Highlights (2/2) Continuing Operations¹ CHF million Lonza HY 2022 HY 2021 YoY (in %) CORE EPS basic (CHF) 7.29 6.99 4.3 EPS Basic (CHF) 6.68 3.51 90.3 CORE EPS Diluted (CHF) 7.28 6.97 4.4 EPS Diluted (CHF) 6.67 3.50 90.6 Change of Net Working Capital (492) (237) 107.6 Capital Expenditures 841 474 77.4 Operational Free Cash Flow (331) 243 Number of Employees 17,154 14,678 (236.2) 16.9 (Full-Time Equivalent) Total Group² CHF million Net debt Debt-equity ratio Net Debt/ CORE EBITDA ratio HY 2022 HY 2021 Change (in %) (221) (958) (76.9) (0.02) (0.12) (0.09) (77.8) (0.53) (77.4) All financial information referring to "continuing operations" are exclusive of the Specialty Ingredients business, that was sold on 1 July 2021 and therefore reported as discontinued operations 2Total Group including discontinued operations CORE definition: See appendix 28#29Event Calendar and Contacts Lonza Upcoming Roadshows 30-31 August 2022 2 September 2022 14-15 September 2022 28 September 2022 Jefferies, London ZKB, Zurich Bank of America, New York & Boston Citi European Healthcare Bus Tour Investor Inquiries: Lyle Wheeler Head of Investor Relations M +41 79 154 9522 [email protected] Next Financial Results Announcement 25 January 2023 Full-Year Results 2022 Information about investor relations events is constantly updated on the website: www.lonza.com/about-lonza/investor-relations Media Inquiries: Victoria Morgan Head of External Communications T +41 61 316 2283 [email protected] 29#30CORE Definition Lonza We believe that disclosing CORE results of the Group's performance enhances the financial markets' understanding because the CORE results enable better year-on-year comparisons. "" Therefore, the CORE results exclude exceptional expenses and income related to e.g. restructuring, environmental-remediation, acquisitions and divestitures, impairment and reversal of impairment of assets, which can differ significantly from year to year. For this same reason, Lonza uses these CORE results in addition to IFRS as important factors in internally assessing the Group's performance. In Lonza's 2022 Alternative Performance Measures Report, the reconciliation of IFRS to CORE results provides further details on the adjustments. 30#31Additional Information and Disclaimer Lonza Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual. Forward-looking statements contained herein are qualified in their entirety as there are certain factors that could cause results to differ materially from those anticipated. Any statements contained herein that are not statements of historical fact (including statements containing the words "outlook," "guidance," "believes," "plans," "anticipates," "expects," "estimates" and similar expressions) should be considered to be forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainty. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements, including the timing and strength of new product offerings; pricing strategies of competitors; the company's ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; difficulty to maintain relationships with employees, customers and other business partners; and changes in the political, social and regulatory framework in which the company operates, or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. In particular, the assumptions underlying the Outlook 2022 herein may not prove to be correct. The statements in the section on Outlook 2022 constitute forward-looking statements and are not guarantees of future financial performance. Lonza's actual results of operations could deviate materially from those set forth in the section on Outlook 2022 as a result of the factors described above or other factors. Investors should not place undue reliance on the statements in the section on Outlook 2022. Except as otherwise required by law, Lonza disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after this presentation was published. 31